Wire · opportunities
HF Commentaries: Adipokine Hypothesis For CpcPH-HFpEF; AI in EHR Analysis
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
New research suggests that treating heart failure patients with preserved ejection fraction and combined post- and precapillary pulmonary hypertension by targeting activin A with sotatercept yields better outcomes than traditional vasodilators. Additionally, AI-enabled tools promise to unlock detailed clinical insights from unstructured electronic health records, enhancing heart failure research and care.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You can now explore adipokine-targeted therapies like sotatercept as a promising new route for difficult heart failure cases that vasodilators fail. AI in electronic health records opens doors for cheaper, faster patient identification and trial recruitment if you embed clinician oversight upfront.
◆ Coverage
1 source · 25 Sep 2026
◆ Related on Wire
◆ Topics